Stature as a prognostic factor in cystic fibrosis survival

被引:125
作者
Beker, LT
Russek-Cohen, E
Fink, RJ
机构
[1] Childrens Natl Med Ctr, Pediat Clin Res Ctr, Childrens Res Inst, Washington, DC 20010 USA
[2] Childrens Natl Med Ctr, Dept Allergy & Pulm Med, Washington, DC 20010 USA
[3] Univ Maryland, Dept Anim Sci, Biometr Program, College Pk, MD 20742 USA
关键词
D O I
10.1016/S0002-8223(01)00113-4
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objective/Design This study provides a longitudinal analysis of the National Cystic Fibrosis Patient Registry to determine if height-for-age percentile would be a useful predictor of survival. Subjects All patients were selected from the national registry (n=19,000) maintained by the Cystic Fibrosis Foundation's 115 accredited Cystic Fibrosis Care Centers in the United States. Inclusion in our analysis required that subjects were born between 1980 and 1989; had a minimum of 4 records each; the subject was alive at age 7; and the subject had a recorded height measurement at age 7 to 8 (n=2,773). Statistical Analysis The Cox proportional hazards model was used to compare height-for-age with survival. We recorded whether a subject was less than the 5th National Center for Health Statistics (NCHS) percentile at age 5 and then in a separate analysis at age 7. Cohort effect was coded as "1" if they were born before 1982 and "0" otherwise. Results Stature is a significant prognostic indicator of survival. The relative hazard associated with height below the 5th NCHS percentile for age was significant for both males and females. In males at age 5 the relative hazard was 2.9, [95% confidence interval (CI) 1.23, 6.91; P < .02] and at age 7 it was 6.3 (95% Cl 2.1, 18.8; P < .001). The relative hazard in females at age 5 was 4.3 (95% Cl 2.4,7.3; P < .0001) and at age 7 was 5.8 (95% Cl 2.5,13.1; P < .0001). Application These highly significant relative hazard values strongly suggest that shorter patients are much more likely to die before taller patients. The dietetic professional should consider using height-for-age as an effective screening tool to identify patients at risk. Based on these data, short stature should not be considered benign to patients with cystic fibrosis. The CF team, clinicians, family, and patients need work together to maximize linear growth through medical and nutritional intervention.
引用
收藏
页码:438 / 442
页数:5
相关论文
共 46 条
  • [1] [Anonymous], STAT ANAL FAILURE TI
  • [2] EFFICACY OF PANCREATIC-ENZYME SUPPLEMENTATION IN CHILDREN WITH CYSTIC-FIBROSIS - COMPARISON OF 2 PREPARATIONS BY RANDOM CROSSOVER STUDY AND A RETROSPECTIVE STUDY OF THE SAME PATIENTS AT 2 DIFFERENT AGES
    ANSALDIBALOCCO, N
    SANTINI, B
    SARCHI, C
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1988, 7 : S40 - S45
  • [3] COMPARISON OF WEIGHT-BASED DOSAGES OF ENTERIC-COATED MICROTABLET ENZYME PREPARATIONS IN PATIENTS WITH CYSTIC-FIBROSIS
    BEKER, LT
    FINK, RJ
    SHAMSA, FH
    CHANEY, HR
    KLUFT, J
    EVANS, E
    SCHIDLOW, DV
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1994, 19 (02) : 191 - 197
  • [4] BEKER LT, 1998, CYSTIC FIBROSIS CTR
  • [5] Nutrition in adults with cystic fibrosis
    Bell, SC
    Bowerman, AR
    Davies, CA
    Campbell, IA
    Shale, DJ
    Elborn, JS
    [J]. CLINICAL NUTRITION, 1998, 17 (05) : 211 - 215
  • [6] BRADY MS, 1992, J AM DIET ASSOC, V92, P813
  • [7] EFFECTIVENESS AND SAFETY OF SMALL VS LARGE DOSES OF ENTERIC COATED PANCREATIC-ENZYMES IN REDUCING STEATORRHEA IN CHILDREN WITH CYSTIC-FIBROSIS - A PROSPECTIVE RANDOMIZED STUDY
    BRADY, MS
    RICKARD, K
    YU, PL
    EIGEN, H
    [J]. PEDIATRIC PULMONOLOGY, 1991, 10 (02) : 79 - 85
  • [8] Colin A A, 1994, Pediatr Rev, V15, P192, DOI 10.1542/pir.15-5-192
  • [9] CYSTIC-FIBROSIS - MOLECULAR-BIOLOGY AND THERAPEUTIC IMPLICATIONS
    COLLINS, FS
    [J]. SCIENCE, 1992, 256 (5058) : 774 - 779
  • [10] Corey M, 1996, AM J EPIDEMIOL, V143, P1007, DOI 10.1093/oxfordjournals.aje.a008664